KRYS

Krystal Biotech, Inc. (KRYS) - Q1 2026 10-Q Summary

Business Context and Reporting Period

This summary covers the quarterly period ended March 31, 2026. Krystal Biotech is a commercial-stage biotechnology company focused on genetic medicines. Its primary revenue driver is VYJUVEK (beremagene geperpavec-svdt), a gene therapy approved in the U.S., EU, and Japan for the treatment of dystrophic epidermolysis bullosa (DEB). The company operates as a single segment and maintains two in-house commercial-scale manufacturing facilities.

Key Financial Metrics

Note: The company reported no long-term debt. Total liabilities were $120.2 million, primarily consisting of accrued rebates ($70.7 million) and lease liabilities.

Material Changes vs. Prior Period

• Revenue Growth: Net product revenue increased 32% year-over-year to $116.4 million. This growth was driven by expanded sales in Europe (Germany, France) and Japan, where the company launched in late 2025, alongside continued U.S. growth.
• Profitability: Net income rose 57% to $55.9 million. Operating income increased 48% to $53.7 million, reflecting strong gross margins (95%) and effective cost management relative to revenue growth.
• Expense Trends:
  • SG&A: Increased 26% ($8.4 million) due to higher payroll, global commercialization costs, and professional fees.
  • R&D: Increased 8% ($1.1 million), driven by pipeline programs (KB111, KB407, KB803) and manufacturing costs, partially offset by lower regulatory fees for VYJUVEK.
• Cash Flow: Operating cash flow surged to $80.4 million, a significant improvement over the prior year's $31.0 million. This was largely due to the absence of a $31.3 million legal settlement payment made in Q1 2025 and higher net income.

Outlook, Risks, and Management Commentary

• Liquidity: Management stated that cash, cash equivalents, and short-term investments of approximately $823.4 million are sufficient to fund operations for at least the next 12 months.
• Commercial Expansion: Pricing negotiations are ongoing in Germany (expected completion H2 2026) and France (expected completion 2027). Discussions are underway for Italy and Spain for potential H2 2026 launches.
• Pipeline Milestones:
  • KB803 (Ocular DEB): Enrollment for the Phase 3 IOLITE study completed in April 2026; top-line results expected before year-end.
  • KB801 (Neurotrophic Keratitis): Enrollment ongoing in the EMERALD-1 registrational study; results expected before year-end.
  • KB407 (Cystic Fibrosis): Initiated an open-label repeat-dose study in April 2026; registrational study design expected H2 2026.
  • KB707 (Oncology): Prioritized inhaled formulation for NSCLC; received Regenerative Medicine Advanced Therapy designation in February 2026.
• Risks & Contingencies:
  • Legal: The company is cooperating with a U.S. Department of Justice inquiry regarding its sponsored genetic testing program. A stockholder derivative lawsuit regarding director compensation has reached an agreement in principle for settlement, which is not expected to be material.
  • Regulatory: Future revenue depends on successful pricing negotiations and reimbursement approvals in international markets.

Investor Verification Checklist

• International Pricing: Verify the timeline and outcome of pricing negotiations in Germany and France, as these are critical for sustaining revenue growth outside the U.S.
• Rebate Accruals: Monitor the "Accrued rebates" line item ($70.7 million), which represents a significant liability and potential volatility in net revenue recognition.
• Clinical Readouts: Track the upcoming top-line data releases for KB803 (IOLITE) and KB801 (EMERALD-1) later in 2026, which are pivotal for pipeline valuation.
• DOJ Inquiry: Watch for any updates regarding the Department of Justice investigation into the genetic testing program, as the potential financial impact is currently unquantifiable.
• Manufacturing Capacity: Confirm the utilization rates of the two in-house CGMP facilities as demand for VYJUVEK scales globally.